EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Dapagliflozin on Gut Microbiota and Plasma Metabolomic Profiles in Patients With Heart Failure

Ying Zhang, Yan Liu, Qingqing Liu, Qingling Zhang, Wenjing Zhu, Chao Ma, Zhen Zhu, Zhong Fang, Xiaodong Xu

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl46142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Ying Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The People's Hospital of Chizhou, 247100 Chizhou, Anhui, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Glucosides, Benzhydryl Compounds, Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2023 Chizhou City major science and technology special project and Anhui Provincial Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Although dapagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated significant cardiovascular benefits in large clinical trials, the underlying mechanisms beyond glucose lowering remain incompletely understood. Increasing evidence suggests that gut microbiota and its metabolites may contribute to HF progression through gut–heart axis interactions.

Methods

In this study, a total of 135 individuals with HF were recruited, comprising 84 patients treated with dapagliflozin (Y group) and 51 receiving conventional therapy (N group). Gut microbial communities were characterized through 16S rRNA gene sequencing to evaluate compositional structure, diversity metrics, and taxa differences between groups. Untargeted metabolomic profiling of plasma samples was conducted to identify significantly altered metabolites and enriched metabolic pathways. Furthermore, the interrelationships between gut bacterial taxa and circulating metabolites were systematically explored to delineate potential microbiome–metabolome interactions.

Results

Dapagliflozin treatment significantly altered gut microbial composition (p < 0.05, permutational multivariate analysis of variance [PERMANOVA]), characterized by increased Prevotella, Akkermansia, Collinsella, and Fusobacterium, and reduced Bacteroides, Parabacteroides, Subdoligranulum, and Bifidobacterium in the dapagliflozin group, whereas control-enriched taxa included Lachnoclostridium and the Ruminococcus gauvreauii group. Fourteen plasma metabolites were differentially abundant between groups, including higher levels of O-phospho-L-threonine and epiandrosterone in the dapagliflozin group, while salicyluric acid and L- (+)-rhamnose were enriched in the control group. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated alterations in amino acid and one-carbon metabolism, as well as carbohydrate and steroid-related pathways. Correlation analysis revealed that Collinsella was positively associated with fludarabine phosphate (p < 0.05), whereas Akkermansia and Paraprevotella showed negative correlations with maslinic acid and phospho-L-valine, respectively (p < 0.01 to p < 0.001).

Conclusion

Dapagliflozin modulates gut microbiota composition and circulating metabolic signatures in HF patients, supporting a potential gut–heart axis mechanism contributing to its cardioprotective effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeGlucosidesBenzhydryl CompoundsHeart FailureMetabolomeSodium-Glucose Transporter 2 InhibitorsHumansMaleFemaleAgedMiddle AgedMetabolomicsBacteriaRNA, Ribosomal, 16S

Stichwörter der Autor:innen

dapagliflozingastrointestinal microbiomegut–heart axisheart failuremetabolomics

Substanzen

GlucosidesBenzhydryl CompoundsdapagliflozinSodium-Glucose Transporter 2 InhibitorsRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Cardiology, The People's Hospital of Chizhou, 247100 Chizhou, Anhui, China.
  • Research and Development Center, Center of Human Microecology Engineering and Technology of Guangdong Province, 510700 Guangzhou, Guangdong, China.

Förderung

  • 2023 Chizhou City major science and technology special project and Anhui Provincial Key Research and Development Program

Zitieren

APA

Zhang, Y., Liu, Y., Liu, Q., Zhang, Q., Zhu, W., Ma, C., Zhu, Z., Fang, Z., & Xu, X. (2025). Impact of Dapagliflozin on Gut Microbiota and Plasma Metabolomic Profiles in Patients With Heart Failure. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl46142

Vancouver

Zhang Y, Liu Y, Liu Q, Zhang Q, Zhu W, Ma C, et al. Impact of Dapagliflozin on Gut Microbiota and Plasma Metabolomic Profiles in Patients With Heart Failure. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl46142

BibTeX
@article{Zhang2025,
  author = {Zhang, Ying and Liu, Yan and Liu, Qingqing and Zhang, Qingling and Zhu, Wenjing and Ma, Chao and Zhu, Zhen and Fang, Zhong and Xu, Xiaodong},
  title = {Impact of Dapagliflozin on Gut Microbiota and Plasma Metabolomic Profiles in Patients With Heart Failure},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl46142}
}
Kostenlos starten →